Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
HIV Eradication: One Step Closer
Life Expectancy With HIV Increases Dramatically
Mouth Full of Problems: A Crisis in HIV Dental Care
New Technology Finds Meds That Might Flush Out Hidden HIV Reservoirs
New Hope for HIV Eradication
Personalized Therapeutic Vaccine Shows Promise
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

May 5, 2009

Lower-Dose ARVs to Be Tested in New Gates-Funded Program

Can using lower doses of certain antiretrovirals (ARVs) deliver a high degree of effectiveness while reducing the risk of side effects and the cost associated with HIV treatment? A series of studies, funded with a $12.4 million grant from the Bill & Melinda Gates Foundation, is determined to find out.

According to an aidsmap report, the first study in the ENCORE (Evaluation of Novel Concepts in Optimization of Antiretroviral Efficacy) research program will be a 700-person clinical trial comparing two doses of Sustiva (efavirenz)—the standard dose (600 mg once daily) and a lower dose (400 mg once daily). Reducing the dose by one third would likely translate into significant cost savings—a key issue in resource-poor countries—and might cause fewer side effects, including central nervous system problems.

ENCORE, led by Sydney-based researchers Sean Emery, MD, and David Cooper, MD, will begin recruiting patients for its first study during the second half of 2009, with sites in Europe, Asia, Australia, Latin America and North America. Results from the 96-week efavirenz dose comparison are expected by 2013.

The research program will also explore lower doses of Epivir (lamivudine) and Kaletra (lopinavir/ritonavir). Other ARVs suggested to be effective at lower doses include Retrovir (zidovudine), Reyataz (atazanavir) and Zerit (stavudine).

Search: Gates, ENCORE, efavirenz, Sustiva, dosing, dose, side effects, Kaletra, Epivir, Emery, Cooper


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 2 (of 2 total)    

L Fontenot, New Orleans, 2009-08-10 15:44:29
I have been taking lower does since Jan 2006. I slowly reduced, got tested, remained undetectable, reduced again and again. Now I take 80% less dosage than prescribed and my t-cells are 100-200 higher every testing. I feel better and have less side effects. I have extra meds left over and wish I could donate them. Thank you

Joseph, Gainesville, 2009-05-09 07:47:24
Against my doctor's advice, I have taken my HIV meds only every other day for more than 2 years and I have some of the best labs ever. My viral load is virtually undetectable and T4 cells average between 600 & 700. I take Sustiva-600mg, Viread-300mg, Reyataz-200mg & Norvir-100mg.

comments 1 - 2 (of 2 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

CROI 2009
Montréal, Canada
February 8-11, 2009


48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy